Does transesophageal echocardiographic demonstration of a patent foramen ovale in patients with a recent cerebral ischemic event change anticoagulation therapy?

J Am Soc Echocardiogr. 2005 Apr;18(4):357-61. doi: 10.1016/j.echo.2004.09.027.

Abstract

Background: Patent foramen ovale (PFO) is commonly demonstrated by transesophageal echocardiography (TEE) in patients with a recent transient ischemic attack or stroke. Our purpose was to determine how the TEE visualization of a PFO alters anticoagulation therapy.

Methods: We retrospectively identified 100 patients with transient ischemic attack or stroke referred for TEE; 50 had a PFO and 50 did not (control patients).

Results: Both groups were similar in regard to age, sex, the occurrence of transient ischemic attack versus stroke, and history of stroke. The PFO group had a higher incidence of a mobile interatrial septum, interatrial septal aneurysm, or both ( P < .001 by Fisher exact test). Both groups had similar pre-TEE aspirin, other antiplatelet, and warfarin use. After TEE, warfarin was instituted in 8 of 50 patients with PFO versus 2 of 50 in the control group ( P = .05) and aspirin use was discontinued in 9 of 50 patients with PFO versus 3 of 50 in the control group ( P = .12).

Conclusion: The main effect of demonstrating a PFO by TEE after an ischemic cerebral event was the institution of warfarin; there was a trend toward discontinuing aspirin.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • Case-Control Studies
  • Echocardiography, Transesophageal*
  • Female
  • Heart Septal Defects, Atrial / complications
  • Heart Septal Defects, Atrial / diagnostic imaging*
  • Humans
  • Ischemic Attack, Transient / drug therapy*
  • Ischemic Attack, Transient / etiology*
  • Male
  • Middle Aged
  • Retrospective Studies
  • Stroke / drug therapy*
  • Stroke / etiology*

Substances

  • Anticoagulants